2,839 bottles made by Sun Pharma Inc being recalled in US

The recall is due to failed dissolution specifications

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries in Mumbai. Photo: Reuters
A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries in Mumbai. Photo: Reuters
Press Trust of India New Delhi
1 min read Last Updated : Jun 22 2016 | 4:08 PM IST
As many as 2,839 bottles of anti-bacterial medicine Nitrofurantoin Oral Suspension manufactured by Sun Pharmaceutical Industries are being recalled in the US market on account of failed dissolution specifications.

The ongoing nationwide voluntary recall by Nostrum Laboratories Inc for Nitrofurantoin Oral Suspension, USP, 25 mg/5 mL is a class II recall, according to the latest enforcement report on USFDA site.

The 2,839 bottles were manufactured and distributed by Sun Pharmaceutical Industries Inc, it added.

Also Read

Citing reasons for the recall, the United States Food and Drug Administration (USFDA) said was due to "failed dissolution specifications."

Nitrofurantoin oral suspension, USP is specifically indicated for the treatment of urinary tract infections.

As per the USFDA, a class II recall is initiated in a "situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Sun Pharma

First Published: Jun 22 2016 | 2:22 PM IST

Next Story